Sanofi
![Sanofi](https://api.admiralmarkets.com/trade_icons/bright-128/SNY.png)
Fermé
57.74 -0.89
Résumé
Variation du prix de l'action
24h
Min
57.61
Max
57.79
Revenu | -20M 1.1B |
---|---|
Ventes | 262M 11B |
P/E Moyenne du Secteur | 25.1 103.001 |
BPA | 0.455 |
Marge bénéficiaire | 9.78 |
EBITDA | -136M 2B |
Recommandations | Achat |
---|---|
Prévisions sur 12 Mois | +0.47 upside |
Capitalisation Boursière | 142B |
---|---|
Ouverture précédente | 58.63 |
Clôture précédente | 57.74 |
Score Technique
By Trading Central
Confiance
Neutral Evidence
Sanofi Graphique
Actualités Associées
Comparaison
Variation de prix
Sanofi prévision
Objectif de Prix
By TipRanks
0.47% hausse
Prévisions sur 12 Mois
Moyen 58 USD 0.47%
Haut 60 USD
Bas 56 USD
Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
EBITDA
Bénéfice d'exploitation
$
À Propos Sanofi
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.